Paul Schimmel bought $185k of ATYR
director at aTYR PHARMA INC. 100,000 shares at an average of $1.85, traded Jul 22, 2024, filed Jul 24, 2024.
Score components
- +15RoleDirector
- +12Trade size$185k at market
- +6Relative to holdingsHoldings up 32%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.1%, 3m +69.9%, 6m +81.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-086159, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 22, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +41,052 | $1.74 | $72k | 354,075 | Jul 24, 2024 |
| Jul 23, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +6,648 | $1.82 | $12k | 360,723 | Jul 24, 2024 |
| Jul 24, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +52,300 | $1.93 | $101k | 413,023 | Jul 24, 2024 |
Related signals
Other insiders at aTYR PHARMA INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | ATYRbuy aTYR PHARMA INC | Paul Schimmel director | $50k 100,000 shares | +15% | |
| 22Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $1,521 1,558 shares | -4% | |
| 15Weak | aTYR PHARMA INC | Nancy Denyes General Counsel | $1,091 1,118 shares | -3% | |
| 25Weak | aTYR PHARMA INC | Sanjay Shukla President and CEO | $3,655 3,745 shares | -2% | |
| 57Moderate | ATYRbuy aTYR PHARMA INC | Paul Schimmel director | $912k 1,000,000 shares | +242% | |
| 25Weak | ATYRbuy aTYR PHARMA INC | Jane A Gross director | $15k 3,750 shares | +63% | |
| 15Weak | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $4,740 1,254 shares | -4% | |
| 8Weak | aTYR PHARMA INC | Nancy Denyes General Counsel | $3,398 899 shares | -3% | |
| 40Moderate | aTYR PHARMA INC | Nancy Denyes General Counsel | $9,276 5,000 shares | +29% | |
| 47Moderate | aTYR PHARMA INC | Jill Marie Broadfoot Chief Financial Officer | $8,950 5,000 shares | +22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.